Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

NCT ID: NCT00093821

Last Updated: 2013-06-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-09-30

Brief Summary

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the dose-limiting toxicity and maximum tolerated dose (MTD) of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in pediatric patients with recurrent or refractory leukemia or selected solid tumors.

II. Determine the levels of key proteins known to influence cancer cell survival and proliferation in patients treated with this drug at the MTD.

SECONDARY OBJECTIVES:

I. Determine the pharmacokinetics of this drug in these patients. II. Evaluate effects of genetic polymorphisms known to alter the activity of enzymes involved in the metabolism of this drug.

III. Correlate the alteration of fludeoxyglucose F18 accumulation with tumor response in patients treated with this drug.

OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (leukemia vs solid tumor).

Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of tanespimycin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD.

Patients are followed for 30 days.

Conditions

Childhood Chronic Myelogenous Leukemia; Childhood Desmoplastic Small Round Cell Tumor; Disseminated Neuroblastoma; Metastatic Childhood Soft Tissue Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (tanespimycin)

Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD.

Group Type: EXPERIMENTAL

tanespimycin

Intervention Type: DRUG

Given IV

pharmacological study

Intervention Type: OTHER

Correlative studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Interventions

tanespimycin

Given IV

Intervention Type: DRUG

pharmacological study

Correlative studies

Intervention Type: OTHER

laboratory biomarker analysis

Correlative studies

Intervention Type: OTHER

Other Intervention Names

17-AAG; pharmacological studies

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed diagnosis of 1 of the following malignancies:

• Leukemia

• Lymphoid, myeloid, or mixed lineage
• Relapsed (in second or greater relapse) or refractory disease, confirmed by 1 of the following:

• Bone marrow relapse, defined as either M3 bone marrow (> 25% blasts in the bone marrow aspirate) OR M2 bone marrow (5-25% blasts in the bone marrow aspirate) at any time after complete remission is attained
• CNS relapse, defined as at least 5 WBC/mL by cytospin of any cerebrospinal fluid (CSF) specimen OR less than 5 WBC/mL by cytospin of 2 consecutive CSF specimens obtained >= 4 weeks apart and having definitive confirmation that blasts are derived from the original leukemic clone by molecular cytogenetics, multiparameter flow cytometry, or immunostaining of >= 2 antigens
• Patients with underlying chronic myeloid leukemia must have > 25% blasts in the bone marrow aspirate
• Patients with M3 bone marrow AND extramedullary sites of disease, other than leptomeningeal disease, are eligible
• Solid tumor

• One of the following tumor types:

• Neuroblastoma
• Ewing's sarcoma
• Osteosarcoma
• Desmoplastic small round cell tumor
• Rhabdomyosarcoma
• Progressed after prior standard therapy OR no effective standard therapy exists
• Measurable or nonmeasurable disease
• No known brain metastases
• No active leptomeningeal leukemia, defined by the following criteria:

• WBC > 5/mm^3 in cerebrospinal fluid (CSF)
• Unequivocal confirmation of leukemic blasts in CSF by cell morphology
• No symptomatic CNS disease (e.g., cranial nerve abnormalities) without cytologic abnormality in CSF
• Performance status - Karnofsky 70-100% (for patients > 10 years of age)
• Performance status - Lansky 70-100% (for patients =< 10 years of age)
• More than 8 weeks
• Absolute neutrophil count >= 750/mm^3
• Platelet count >= 75,000/mm^3 (transfusion independent)
• Hemoglobin >= 8.5 g/dL (transfusion allowed)
• Bilirubin < 1.5 mg/dL
• ALT and AST =< 2.5 times upper limit of normal (ULN)
• INR =< 1.5 times ULN
• Albumin > 2.0 g/dL
• Creatinine =< 1.5 times ULN for age
• Creatinine clearance or radioisotope glomerular filtration rate > 60 mL/min
• Ejection fraction >= 50%
• Shortening fraction >= 28%
• QTc < 450 msec for men (470 msec for women)

• No congenital long QT syndrome
• LVEF > 40% by MUGA
• No symptomatic congestive heart failure
• No cardiac arrhythmia
• No New York Heart Association class III or IV heart failure
• No myocardial infarction within the past year
• No uncontrolled dysrhythmias
• No poorly controlled angina
• More than 12 months since active ischemic heart disease
• No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation >= 3 beats in a row)
• No left bundle branch block
• No other significant cardiac disease
• No pulmonary fibrosis by radiography
• No ongoing or active bacterial or fungal infection
• No other uncontrolled illness
• No psychiatric illness or social situation that would preclude study compliance
• No history of serious allergic reaction attributed to eggs or dimethyl sulfoxide
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Recovered from all immunotherapy
• At least 6 months since prior allogeneic stem cell transplantation
• At least 3 months since prior autologous stem cell transplantation
• At least 2 weeks since prior biologic agents (e.g., monoclonal antibodies)
• At least 1 week since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• Recovered from all prior chemotherapy
• At least 2 weeks since prior chemotherapy (for patients with leukemia only)
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) (for patients with solid tumors)
• No prior oxaliplatin
• No concurrent corticosteroids except for the treatment of adrenal crises in patients with suppressed hypothalamic-pituitary-adrenal axis response OR for treatment of allergic reactions to medications or blood products
• Recovered from all prior radiotherapy
• At least 6 months since prior radiotherapy to >= 50% of the pelvis
• At least 6 months since prior radiotherapy to substantial bone marrow, including total body irradiation
• At least 4 weeks since prior local (small port) radiotherapy
• No prior radiotherapy to the heart
• At least 1 week since prior retinoids
• No concurrent antiretroviral therapy for HIV-positive patients
• No concurrent medication to control arrhythmias
• No concurrent medications that prolong or may prolong QTc interval
• No other concurrent investigational agents
• No other concurrent anticancer therapy

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tanya Trippett

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Countries

United States

Other Identifiers

04-069

Identifier Type: -

Identifier Source: secondary_id

POETIC-MSKCC-04069

Identifier Type: -

Identifier Source: secondary_id

CDR0000391010

Identifier Type: -

Identifier Source: secondary_id

NCI-6323

Identifier Type: -

Identifier Source: secondary_id

MSKCC-04069

Identifier Type: -

Identifier Source: secondary_id

U01CA069856

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2012-01456

Identifier Type: -

Identifier Source: org_study_id